Scientific Symposium

• Opening session CTOS (1 pm to 5 pm)

• CTOS reception (5pm to 6pm)

• Dinner/Consensus Discussion (6pm to 9 pm)– Panel

• George Demetri, MD• Scott Schuetze, MD, PhD• Laurence Baker, DO (moderator)

P=Participating NP=Not Participating *Awaiting Contract **No longer accruing

start date

GleevecNov ’01

G Vs. Gem/TXT STSJan ’03

Columbia 15 NP

Emory NP P*

Mayo NP 6

MD Anderson 45 20

U of Michigan 69 29

Memorial Sloan Kettering 34 11

National Cancer Institute NP P

Partners

Dana Farber

Massachusetts General

NP 1

UofCalifornia Los Angeles NP P*

Washington Cancer Center 14 10

Lutheran General ** 42 10

Total 219 87

CR

PR

SDSD

CR

PR

PD PD

Month 2 Month 4

PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN

PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN

The hierarchical model allows data from each subtype to provide information about parameters in all other subtypes

It avoids two undesirable approaches, conducting :

- One trial, assuming one common parameter, ignoring the subtypes, or

- Separate trials that ignore each others’ data

User-friendly front ends greatly facilitate trial conduct

0.0 0.2 0.4 0.6 0.8 1.0

-12

-10

-8-6

-4-2

0.0 0.2 0.4 0.6 0.8 1.0

Angiosarcoma

Ewings

Fibrosarcoma

Leiomyosarcoma

Liposarcoma

MFH

Osteosarcoma

PNS

Rhabdomyosarcoma

Synovial

Desmoid

= Pr( Response )

95% Posterior Credible Intervals by Histologic Subtype

Pre-Gleevec

8 weeks on Rx

H &. E

cKIT

74 yo man with myofibroblastic sarcoma

Pre-Gleevec

2 weeks on Rx

H & E

cKIT

65 yo man with malignant fibrous histiocytoma

Planned Studies

• Gemcitabine/docetaxel in bone sarcomas

• Imatinib neoaduvant treatment of DFSP

• AMG 706 Phase II trial in sarcoma

• BMS SRC inhibitor

• Ziopharm active ifosphamide moiety

• Uterine sarcoma adjuvant therapy